Current Gene Therapy
Title:Gene Therapy (Part I)
Volume: 20 Issue: 1
Author(s): Xi-Biao Jia and Zhi-Yao He
Affiliation:
Export Options
About this article
Cite this article as:
Jia Xi-Biao and He Zhi-Yao , Gene Therapy (Part I), Current Gene Therapy 2020; 20 (1) . https://dx.doi.org/10.2174/156652322001200604150311
DOI https://dx.doi.org/10.2174/156652322001200604150311 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center
Current Pharmaceutical Design MET and ALK as Targets for the Treatment of NSCLC
Current Pharmaceutical Design Application of NMR to the Study of Cells and Body Fluids
Current Organic Chemistry Heparin Derivatives as Angiogenesis Inhibitors
Current Pharmaceutical Design A Focus on Heme Oxygenase-1 (HO-1) Inhibitors
Current Medicinal Chemistry Polynuclear Ruthenium, Osmium and Gold Complexes. The Quest for Innovative Anticancer Chemotherapeutics
Current Topics in Medicinal Chemistry Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets Particulate Systems Based on Poly(Lactic-co-Glycolic)Acid (pLGA) for Immunotherapy of Cancer
Current Pharmaceutical Design Harnessing the Natural Pool of Polyketide and Non-ribosomal Peptide Family: A Route Map towards Novel Drug Development
Current Molecular Pharmacology Age-Related Changes in P-Glycoprotein Expression in Senescence- Accelerated Mouse
Current Aging Science Molecular Bases of Liver Cancer Refractoriness to Pharmacological Treatment
Current Medicinal Chemistry The Pim Kinases: New Targets for Drug Development
Current Drug Targets Editorial: [Hot Topic: Molecular Chaperones as Drug Targets]
Current Pharmaceutical Design Nanoparticles vs Cancer: A Multifuncional Tool
Current Topics in Medicinal Chemistry Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Enhancing the Site-Specific Targeting of Macromolecular Anticancer Drug Delivery Systems
Current Drug Targets Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy
Current Pharmaceutical Design Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets